169 related articles for article (PubMed ID: 19145322)
1. Cardioprotective effects of trimetazidine and a combination of succinic and malic acids in acute myocardial ischemia.
Khazanov VA; Kiseliova AA; Vasiliev KY; Chernyschova GA
Bull Exp Biol Med; 2008 Aug; 146(2):218-22. PubMed ID: 19145322
[TBL] [Abstract][Full Text] [Related]
2. Protective effect of trimetazidine on myocardial mitochondrial function in an ex-vivo model of global myocardial ischemia.
Monteiro P; Duarte AI; Gonçalves LM; Moreno A; Providência LA
Eur J Pharmacol; 2004 Oct; 503(1-3):123-8. PubMed ID: 15496306
[TBL] [Abstract][Full Text] [Related]
3. [Treating ischemic heart disease by pharmacologically improving cardiac energy metabolism].
Lopaschuk GD
Presse Med; 1998 Dec; 27(39):2100-4. PubMed ID: 9893703
[TBL] [Abstract][Full Text] [Related]
4. Effects of trimetazidine on mitochondrial respiratory function, biosynthesis, and fission/fusion in rats with acute myocardial ischemia.
Shi W; Shangguan W; Zhang Y; Li C; Li G
Anatol J Cardiol; 2017 Sep; 18(3):175-181. PubMed ID: 28761019
[TBL] [Abstract][Full Text] [Related]
5. Trimetazidine and the contractile response of dysfunctional myocardium in ischaemic cardiomyopathy.
Belardinelli R
Rev Port Cardiol; 2000 Nov; 19 Suppl 5():V35-9. PubMed ID: 11206102
[TBL] [Abstract][Full Text] [Related]
6. The potential benefits of trimetazidine in patients with diabetes and ischemic cardiomyopathy.
Korantzopoulos P; Kountouris E; Siogas K; Galaris D
Am Heart J; 2004 Dec; 148(6):e31; author reply e32. PubMed ID: 15632868
[No Abstract] [Full Text] [Related]
7. Metabolic treatment of myocardial ischaemia.
Ferrari R
Eur Heart J; 1999 Aug; 20(16):1144-5. PubMed ID: 10448019
[No Abstract] [Full Text] [Related]
8. Beneficial effects of trimetazidine in ex vivo working ischemic hearts are due to a stimulation of glucose oxidation secondary to inhibition of long-chain 3-ketoacyl coenzyme a thiolase.
Lopaschuk GD; Barr R; Thomas PD; Dyck JR
Circ Res; 2003 Aug; 93(3):e33-7. PubMed ID: 12869392
[TBL] [Abstract][Full Text] [Related]
9. Thimerosal attenuates ischaemia-reperfusion arrhythmias in rats: no modification by anti-ischaemic agent trimetazidine or endothelin receptor antagonist bosentan.
Iskit AB; Guc MO
Pharmacol Res; 1996; 34(1-2):17-23. PubMed ID: 8981551
[TBL] [Abstract][Full Text] [Related]
10. Metabolic management of coronary heart disease: adjunctive treatment with trimetazidine decreases QT dispersion in patients with a first acute myocardial infarction.
Kountouris E; Pappa E; Pappas K; Dimitroula V; Karanikis P; Tzimas T; Siogas K
Cardiovasc Drugs Ther; 2001 Jul; 15(4):315-21. PubMed ID: 11800415
[TBL] [Abstract][Full Text] [Related]
11. Trimetazidine demonstrated cardioprotective effects through mitochondrial pathway in a model of acute coronary ischemia.
Dehina L; Vaillant F; Tabib A; Bui-Xuan B; Chevalier P; Dizerens N; Bui-Xuan C; Descotes J; Blanc-Guillemaud V; Lerond L; Timour Q
Naunyn Schmiedebergs Arch Pharmacol; 2013 Mar; 386(3):205-15. PubMed ID: 23263451
[TBL] [Abstract][Full Text] [Related]
12. Treating ischemic heart disease by pharmacologically improving cardiac energy metabolism.
Lopaschuk GD
Am J Cardiol; 1998 Sep; 82(5A):14K-17K. PubMed ID: 9737481
[TBL] [Abstract][Full Text] [Related]
13. Cardioprotective effect of Taurhythman: the experimental study.
Krylova IB; Evdokimova NR; Gavrovskaya LK; Sapronov NS
Adv Exp Med Biol; 2006; 583():535-41. PubMed ID: 17153642
[No Abstract] [Full Text] [Related]
14. Effect of trimetazidine on mitochondrial function and oxidative damage during reperfusion of ischemic hypertrophied rat myocardium.
Guarnieri C; Muscari C
Pharmacology; 1993 Jun; 46(6):324-31. PubMed ID: 8516381
[TBL] [Abstract][Full Text] [Related]
15. [Correction of episodes of transitory myocardial ischemia with trimetazidine in patients with ischemic heart disease combined with type 2 diabetes mellitus].
Petriĭ VV; Mikova NV; Makolkin VI
Kardiologiia; 2007; 47(7):22-5. PubMed ID: 18260890
[TBL] [Abstract][Full Text] [Related]
16. The antianginal agent trimetazidine does not exert its functional benefit via inhibition of mitochondrial long-chain 3-ketoacyl coenzyme A thiolase.
MacInnes A; Fairman DA; Binding P; Rhodes Ja; Wyatt MJ; Phelan A; Haddock PS; Karran EH
Circ Res; 2003 Aug; 93(3):e26-32. PubMed ID: 12869391
[TBL] [Abstract][Full Text] [Related]
17. Myocardial metabolic manipulation: a new therapeutic approach in heart failure?
O'Meara E; McMurray JJ
Heart; 2005 Feb; 91(2):131-2. PubMed ID: 15657211
[TBL] [Abstract][Full Text] [Related]
18. Metabolic management of ischemic heart disease: clinical data with trimetazidine.
Desideri A; Celegon L
Am J Cardiol; 1998 Sep; 82(5A):50K-53K. PubMed ID: 9737486
[TBL] [Abstract][Full Text] [Related]
19. Is the sarcolemmal or mitochondrial K(ATP) channel activation important in the antiarrhythmic and cardioprotective effects during acute ischemia/reperfusion in the intact anesthetized rabbit model?
Das B; Sarkar C
Life Sci; 2005 Jul; 77(11):1226-48. PubMed ID: 15964023
[TBL] [Abstract][Full Text] [Related]
20. Effects of trimetazidine on myocardial preconditioning in anesthetized rats.
Kara AF; Demiryürek S; Celik A; Tarakçioğlu M; Demiryürek AT
Eur J Pharmacol; 2004 Oct; 503(1-3):135-45. PubMed ID: 15496308
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
